Literature DB >> 2157903

Biopsy of occult breast lesions. Analysis of 1261 abnormalities.

J E Meyer1, T J Eberlein, P C Stomper, M R Sonnenfeld.   

Abstract

From January 1, 1987, to December 31, 1988, roentgenographically guided biopsies of 1261 occult breast abnormalities were performed. There were 626 (49.6%) masses and 635 (50.4%) lesions with calcification as the dominant feature. Of the total, 237 (18.8%) were found to be malignant, including 85 cases of ductal carcinoma in situ. Biopsies performed for a mass yielded a 20.8% (130/626) incidence of cancer; and for calcification, 16.9% (107/635). The biopsy results were supported by the interpretations of four radiologists (J.E.M., P.C.S., and M.R.S.) who were practicing at Brigham and Women's Hospital in 22.2% of the total (280), whereas the remaining 981 lesions were discovered on mammograms that were performed and interpreted elsewhere and were referred to our hospital for surgical consultation. The biopsy results of the mammograms from other facilities yielded a positive predictive value of 16.7% (164/981) vs 26.1% (73/280) for the Brigham and Women's Hospital group. This statistically significant difference lends support to the value of a second opinion in patients with biopsy recommendations for occult breast lesions, especially when findings are inconclusive.

Entities:  

Mesh:

Year:  1990        PMID: 2157903

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

1.  Ductal carcinoma in situ: correlations between high-resolution magnetic resonance imaging and histopathology.

Authors:  Yoshihide Kanemaki; Yasuyuki Kurihara; Kyoko Okamoto; Yasuo Nakajima; Mamoru Fukuda; Ichiro Maeda; Futoshi Akiyama
Journal:  Radiat Med       Date:  2007-01-25

2.  Do first opinions affect second opinions?

Authors:  Geva Vashitz; Joseph S Pliskin; Yisrael Parmet; Yona Kosashvili; Gal Ifergane; Shlomo Wientroub; Nadav Davidovitch
Journal:  J Gen Intern Med       Date:  2012-04-27       Impact factor: 5.128

3.  Characterization of mammographic masses based on level set segmentation with new image features and patient information.

Authors:  Jiazheng Shi; Berkman Sahiner; Heang-Ping Chan; Jun Ge; Lubomir Hadjiiski; Mark A Helvie; Alexis Nees; Yi-Ta Wu; Jun Wei; Chuan Zhou; Yiheng Zhang; Jing Cui
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

4.  Lump detection is enhanced in silicone breast models simulating postmenopausal breast tissue.

Authors:  M M McDermott; N C Dolan; J Huang; D Reifler; A W Rademaker
Journal:  J Gen Intern Med       Date:  1996-02       Impact factor: 5.128

5.  Needle biopsy of probably benign nonpalpable breast lesions.

Authors:  F M Hall
Journal:  West J Med       Date:  1994-03

6.  Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors.

Authors:  Jagpreet Chhatwal; Oguzhan Alagoz; Elizabeth S Burnside
Journal:  Oper Res       Date:  2010-11-01       Impact factor: 3.310

7.  Screening mammograms by community radiologists: variability in false-positive rates.

Authors:  Joann G Elmore; Diana L Miglioretti; Lisa M Reisch; Mary B Barton; William Kreuter; Cindy L Christiansen; Suzanne W Fletcher
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

8.  Is needle-directed breast biopsy overused?

Authors:  M W Shields; R S Smith; M F Bardwil; J K Harness
Journal:  West J Med       Date:  1994-03

9.  Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities.

Authors:  G M Fuhrman; G J Cederbom; J S Bolton; T A King; J L Duncan; J L Champaign; D H Smetherman; G H Farr; R R Kuske; W M McKinnon
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

10.  International variation in screening mammography interpretations in community-based programs.

Authors:  Joann G Elmore; Connie Y Nakano; Thomas D Koepsell; Laurel M Desnick; Carl J D'Orsi; David F Ransohoff
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.